The DYNAMIC-III trial enrolled over 1,000 participants diagnosed with stage 3 colon cancer from Australia, New Zealand, and Canada. All patients underwent surgical resection aimed at removing the primary tumor. Approximately six weeks post-surgery, blood samples were collected for analysis of ctDNA, cancer-derived genetic fragments shed into the bloodstream through tumor cell apoptosis or necrosis. Detection of ctDNA after surgery acts as a highly sensitive biomarker for residual microscopic disease lurking beyond the reach of conventional imaging techniques.

Patients were stratified into two categories based on their ctDNA status: “low-risk” if no ctDNA was detectable, and “high-risk” if ctDNA fragments were present in circulation. This molecular categorization then guided randomized treatment allocations, comparing ctDNA-directed adjuvant chemotherapy regimens against standard chemotherapy protocols. The fundamental goal was to determine whether ctDNA testing could safely reduce overtreatment while maintaining cancer-free survival outcomes, representing a leap toward personalized medicine in colorectal oncology.

Professor Jeanne Tie from WEHI, a leading oncologist and the trial’s principal investigator, emphasizes that ctDNA-guided therapy embodies the future of precision oncology in this setting. While current guidelines advocate uniform administration of chemotherapy for all stage 3 colon cancer patients, often resulting in unnecessary exposure to cytotoxic drugs and associated toxicities, ctDNA assays can tailor treatment intensity based on molecular evidence of minimal residual disease (MRD). This nuanced approach ensures patients without detectable tumor DNA avoid the harsh side effects of chemotherapy like oxaliplatin-induced neuropathy without compromising survival chances.

The clinical data underscore the promise of this strategy. Patients categorized as ctDNA-negative post-surgery experienced remarkably favorable outcomes, with an impressive 87 percent remaining disease-free three years later. This suggests that a less aggressive chemo regimen or even omission of chemotherapy can be safe and effective in patients demonstrating molecular remission. Such precision spares patients from the physical and emotional burdens intrinsic to chemotherapy, substantially enhancing quality of life while preserving clinical efficacy.

Conversely, individuals with persistent ctDNA positivity faced a substantially elevated risk of recurrence. The study showed that only about half of these patients remained cancer-free at the three-year mark. Moreover, analysis revealed a dose-response relationship, where increasing ctDNA levels correlated with higher chances of tumor relapse. Importantly, intensification of chemotherapy in this subgroup did not improve outcomes, illuminating an urgent need for novel therapeutic strategies capable of targeting the biological pathways driving resistant or residual disease.

These findings were made possible through a seamless collaboration among several prominent organizations, including the Canadian Cancer Trials Group (CCTG), the Australasian Gastrointestinal Trials Group (AGITG), and the Peter MacCallum Cancer Centre. This multinational, multidisciplinary effort attests to the robustness and generalizability of the results, providing a strong impetus to integrate ctDNA testing into clinical oncology workflows globally.

Dr Jonathan Loree, Canadian senior investigator and DYNAMIC-III trial chair, highlights the study as the most compelling prospective evidence of ctDNA’s prognostic and predictive utility in resected stage 3 colon cancer to date. The trial’s rigorously designed randomized methodology addresses prior limitations in ctDNA research, establishing clinical validity that could fast-track incorporation into treatment guidelines. Dr Loree further stresses that these insights could also pave the way for refinements in other tumor types where MRD biomarkers hold promise.

Colorectal cancer remains a leading cause of cancer morbidity and mortality worldwide, with over 15,000 new diagnoses anticipated in Australia alone in 2024. This novel ctDNA-based liquid biopsy represents a paradigm shift, moving beyond traditional staging and histopathological factors to molecularly informed therapeutic decisions. Such advancements demonstrate how liquid biopsies, an emerging frontier in oncology, can revolutionize early detection of relapse, optimize adjuvant chemotherapy use, and ultimately improve patient survival.

The implications extend beyond clinical outcomes, promising a substantial reduction in healthcare costs and burden on patients’ lives by minimizing unnecessary treatments. By personalizing therapeutic interventions based on real-time molecular surveillance, DYNAMIC-III exemplifies how precision medicine is reshaping cancer care in the 21st century, reaffirming the critical role of translational research and international collaboration in advancing oncology.

In summary, the DYNAMIC-III trial decisively proves that ctDNA can serve as a sensitive, non-invasive biomarker to guide adjuvant chemotherapy in stage 3 colon cancer. This approach spares low-risk patients from unwarranted chemotherapy toxicity while identifying those at genuine high risk who require closer monitoring and potentially novel therapeutic approaches. As the oncology community embraces this innovation, patients stand to benefit from safer, more efficacious, and truly individualized treatment strategies that align with the molecular underpinnings of their disease.

Subject of Research: People

Article Title: Circulating Tumor DNA-Guided Adjuvant Therapy in Locally Advanced Colon Cancer: the Randomized Phase 2/3 DYNAMIC-III Trial

Web References:
10.1038/s41591-025-04030-w

Image Credits: WEHI

Keywords: Colon cancer, Cancer, Circulating tumor DNA, ctDNA, Adjuvant chemotherapy, Precision medicine, Minimal residual disease, Liquid biopsy

By analyzing cfDNA from 18 HGSOC patients with confirmed radiological recurrence, the researchers meticulously tracked variant allele fractions (VAFs) of truncal structural variants (SVs), which represent mutations present in the founding tumor clone. During initial chemotherapy, these truncal SV VAFs declined, reflecting tumor burden reduction and parallel decreases in serum CA-125, a conventional biomarker. Remarkably, all patients showed detectable ctDNA at their first recurrence through these truncal SVs—far exceeding the sensitivity offered by monitoring single gene mutations like TP53 or known tumor suppressors including BRCA1/2 and CDK12. This demonstrates that leveraging truncal SVs as molecular markers enables earlier and more precise detection of residual disease.

The team’s approach to clonal abundance estimation involved aggregating VAFs across clone-specific SVs and adjusting for cancer cell fractions determined via scWGS. Comparisons to high-depth cfDNA whole-genome sequencing validated this methodology, revealing ~92% concordance in identifying dominant clones across multiple samples. Moreover, clone-specific amplifications, visible even at low tumor fractions, confirmed the inferred dominant populations. Correlations between single nucleotide variant (SNV) and SV-based trajectories further solidified these observations, highlighting the robustness and resolution of this multi-faceted approach.

Detailed longitudinal tracking of clonal populations unveiled nuanced therapeutic responses. For instance, patient 044 harbored two main clones at diagnosis: clone B, marked by a high-level ERBB2 amplification, and clone E, lacking this alteration. Front-line chemotherapy effectively eradicated clone E and achieved ctDNA clearance, but clone B persisted as the dominant clone at recurrence, demonstrating resistance to second-line chemo. Intriguingly, subsequent treatment with trastuzumab deruxtecan—an antibody-drug conjugate targeting Her2 (ERBB2)—resulted in complete radiologic remission sustained over three years. This case exemplifies how clonal dynamics informed by cfDNA can identify actionable vulnerabilities fundamental to personalized therapy.

Another compelling example emerged in patient 009, who possessed a germline BRCA1 mutation and derived benefit from PARP inhibitor maintenance. At recurrence, a novel 1.37-kb deletion excising the germline mutation site restored the BRCA1 reading frame—a putative reversion mutation associated with PARP inhibitor resistance. This highlights the tumor’s genomic plasticity during relapse and underscores the critical role of monitoring clonal evolution in anticipating treatment resistance, which often portends poor responses to subsequent therapies.

The investigation also elucidated the role of CCNE1 amplification, a marker linked to chemoresistance in HGSOC. In two patients, clone-specific CCNE1 copy number gains were validated by fluorescence in situ hybridization and correlated with dominant clones at recurrence in one case, whereas in another, a different clone lacking CCNE1 amplification ultimately dominated post-second-line chemotherapy. Notably, the CCNE1-amplified clones also harbored concurrent NOTCH3 or RAB25 amplifications—genes implicated in chemotherapy resistance and disease relapse—revealing that chemoresistance emerges through complex and heterogeneous genomic mechanisms rather than a single alteration.

Adding further depth, analyses of longitudinal surgical tissue samples revealed patterns concordant with cfDNA findings. In patient 026, recurrence cells collected nearly five years postdiagnosis resembled a minor clone present at baseline that underwent whole-genome doubling, elucidating a possible mechanism permitting like-for-like relapse from a rare resistant subpopulation. Such insights reinforce the power of integrating cfDNA and single-cell genomics to capture tumor heterogeneity spatially and temporally, which is crucial for understanding the evolutionary trajectories that underpin disease progression.

The study’s approach provides a transformative framework for real-time monitoring of tumor evolution and therapeutic resistance. Current clinical biomarkers like CA-125, while valuable, lack the granularity to identify specific clonal drivers of relapse. Accurate detection and quantification of clone-specific structural variants in cfDNA represent a notable advancement, enabling earlier intervention, therapeutic tailoring, and potentially better outcomes in a disease plagued by high relapse rates and limited effective treatments.

This research also highlights the diverse genomic landscapes that emerge during recurrence, including chromothripsis, copy-number gains of oncogenes like MYC and FGFR3, and reversion mutations—all contributing to the adaptive capacities of ovarian cancer. Understanding these dynamics at single-cell resolution facilitates precision medicine approaches, where therapeutic strategies can be dynamically adjusted based on the evolving genomic profile of the disease.

Furthermore, the detection of distinct clone-specific amplifications and rearrangements with deep sequencing of cfDNA offers a minimally invasive window into tumor biology, reducing reliance on repeated biopsies that are practically challenging and often risky. The authors demonstrate that cfDNA is a robust substrate for clonal tracking, with potential applications extending beyond ovarian cancer to other malignancies where intratumoral heterogeneity plays a pivotal role.

In essence, this study consolidates a paradigm shift—from static tissue snapshots to dynamic molecular monitoring—ushering in a new era of oncology that embraces tumor evolution as a central consideration in treatment planning and outcome prediction. With ongoing enhancements in sequencing technologies and computational analyses, personalized, evolution-informed therapy may soon become a clinical reality for ovarian cancer patients worldwide.

Intriguingly, the case of patient 044 further validates the clinical utility of molecularly targeted therapies guided by detailed clonal analysis, revealing how upfront chemotherapy can selectively eliminate sensitive clones while leaving resistant ones behind—information that standard imaging and biomarkers alone might miss. Such insights empower oncologists to rationally deploy targeted agents at recurrence, transforming patient outcomes.

Moreover, the study accentuates the heterogeneous nature of resistance mechanisms, cautioning against oversimplified biomarkers like CCNE1 amplification as sole predictors of chemoresistance. Comprehensive clonal characterization incorporating multiple genomic features is essential to accurately forecast therapeutic responsiveness and design combinatorial strategies that preempt clonal escape.

Overall, the integration of innovative cfDNA tracking with single-cell genomics presents a powerful toolkit for decoding the evolutionary narratives of cancer, offering hope that the deadly trajectory of ovarian cancer can be intercepted through precise, adaptive interventions tailored to its evolving molecular landscape.

Subject of Research: Clonal evolution and therapeutic resistance in high-grade serous ovarian cancer tracked via cell-free DNA.

Article Title: Tracking clonal evolution during treatment in ovarian cancer using cell-free DNA.

Article References:
Williams, M.J., Vázquez-García, I., Tam, G. et al. Tracking clonal evolution during treatment in ovarian cancer using cell-free DNA. Nature (2025). https://doi.org/10.1038/s41586-025-09580-0

Image Credits: AI Generated

Pembrolizumab, an anti-PD-1 monoclonal antibody, has been a beacon of hope in oncology, particularly due to its ability to unleash the immune system against tumors that employ immune evasion tactics. Tumors deficient in mismatch repair enzymes accumulate mutations rapidly, rendering them hypermutated and theoretically more recognizable by the immune system. MSI-H tumors, a subset notable for their genomic instability, have consistently demonstrated marked responsiveness to immune checkpoint blockade. However, questions remained about the durability of pembrolizumab’s effects beyond initial treatment phases and how best to monitor disease status dynamically.

The study encompasses a comprehensive cohort of patients harboring locally advanced dMMR/MSI-H solid tumors, treated with pembrolizumab over extended periods. Prior investigations mainly focused on short- to mid-term clinical endpoints, such as objective response rates and progression-free survival. Here, the meticulous follow-up extends for several years, revealing robust, sustained anti-tumor activity. Notably, a substantial proportion of patients maintained complete or partial responses well beyond two years, highlighting pembrolizumab’s potential to induce durable remission in this genetically defined subgroup.

What sets this investigation apart is its integration of circulating tumor DNA analysis as a non-invasive biomarker. ctDNA, fragments of genetic material shed into the bloodstream by cancer cells, has emerged as a powerful tool for real-time monitoring of tumor burden. By employing ultra-sensitive assays, the researchers tracked ctDNA levels longitudinally, correlating changes with imaging and clinical outcomes. This approach provides a molecular lens for detecting minimal residual disease or early relapse, even before radiographic progression becomes evident.

The technical sophistication of ctDNA detection owed to next-generation sequencing technologies and error suppression methods, enabling the identification of mutations unique to each patient’s tumor. This allowed for personalized monitoring, whereby fluctuations in tumor-specific ctDNA alleles mirrored the waxing and waning of cancer activity. The study convincingly demonstrated that patients with undetectable ctDNA after initial therapy bore excellent prognoses, while rising ctDNA signaled impending progression, often preceding conventional imaging by months.

Clinicians are particularly intrigued by the potential applications of ctDNA-guided therapy modulation. For patients exhibiting sustained low or undetectable ctDNA, treatment de-escalation or cessation might be feasible, sparing them from unnecessary toxicity and economic burden. Conversely, early molecular relapse detection could prompt timely therapeutic adjustments, such as combination regimens or enrollment into clinical trials, potentially improving outcomes. This paradigm of dynamic treatment tailoring stands to revolutionize personalized oncology.

From a mechanistic standpoint, this work sheds light on the immunobiology underpinning dMMR/MSI-H tumor susceptibility to PD-1 blockade. Hypermutation fosters neoantigen generation, which primes cytotoxic T-cell responses. Pembrolizumab reinvigorates these exhausted immune effectors, enabling durable tumor control. The prolonged clinical benefits observed reinforce the hypothesis that sustained immune activation can lead to functional cures in select patients. Furthermore, the absence of significant late relapses suggests potential immune memory formation, a concept of immense translational importance.

The researchers also emphasize the heterogeneity within MSI-H tumors, noting variable response kinetics and patterns. Certain tumors exhibited initial pseudoprogression — an apparent radiologic worsening due to immune infiltration rather than growth — underscoring the need for integrated biomarker approaches like ctDNA to inform clinical decisions. The identification of such pitfalls enhances physician confidence in managing complex response scenarios, avoiding premature therapy discontinuation.

Importantly, the safety profile of pembrolizumab over extended treatment durations corroborated prior findings, with manageable immune-related adverse events. The long-term tolerability is essential as maintenance immunotherapy strategies gain prominence. The study highlighted that vigilant monitoring, coupled with prompt immunosuppression when necessary, effectively mitigates toxicity without compromising efficacy, enabling sustained patient benefit.

This research also contributes to the broader discourse on tumor evolution under immunologic pressure. Serial ctDNA analyses revealed emergent resistance mutations and clonal dynamics, informing future combination strategies aimed at thwarting immune escape. Understanding these resistance mechanisms at a molecular level paves the way for novel agents targeting complementary pathways, potentially overcoming limitations of current monotherapy approaches.

The translational implications extend beyond dMMR/MSI-H tumors. The ctDNA monitoring framework validated here could be applicable across multiple cancer types and therapeutic modalities, streamlining clinical workflows and enhancing precision medicine. Additionally, the integration of genomic and immunologic biomarkers may facilitate patient stratification, optimizing immunotherapy allocation and cost-effectiveness.

Collaborative efforts involving multidisciplinary teams, including oncologists, molecular biologists, bioinformaticians, and immunologists, were pivotal in executing this landmark study. The robust dataset and rigorous analytical methods provide a compelling evidence base supporting regulatory considerations for ctDNA as a surrogate endpoint in clinical trials.

As immunotherapy cements its role as a cornerstone of cancer care, studies like this illuminate the path toward durable cures and personalized strategies. The marriage of cutting-edge immunotherapeutic agents and innovative biomarker technologies heralds a new era where real-time tumor monitoring guides adaptive interventions, maximizing patient outcomes.

The future outlook is promising. Ongoing trials are expanding upon these findings, assessing pembrolizumab in combination with other immune modulators, targeted therapies, and novel agents. Integration of artificial intelligence-driven analytics to interpret ctDNA data may further refine treatment personalization. Ultimately, the goal is to transform cancer from a fatal diagnosis into a manageable or even curable condition through immunologic mastery.

In summary, the long-term efficacy of pembrolizumab documented in locally advanced dMMR/MSI-H solid tumors sets a new standard for durable immunotherapy responses. The incorporation of ctDNA as a dynamic biomarker represents a milestone in oncology, enabling precision monitoring and individualized care. These advances underscore the profound impact of harnessing the immune system and molecular diagnostics to outsmart cancer’s complexity, heralding a transformative era for patients and clinicians alike.

Subject of Research: Long-term therapeutic efficacy of pembrolizumab and the clinical utility of circulating tumor DNA (ctDNA) in locally advanced dMMR/MSI-H solid tumors.

Article Title: Long-Term Efficacy of Pembrolizumab and the Clinical Utility of ctDNA in Locally Advanced dMMR/MSI-H Solid Tumors.

Article References:
LaPelusa, M., Qiao, W., Iorgulescu, B. et al. Long-Term Efficacy of Pembrolizumab and the Clinical Utility of ctDNA in Locally Advanced dMMR/MSI-H Solid Tumors. Nat Commun 16, 4514 (2025). https://doi.org/10.1038/s41467-025-59615-3

Image Credits: AI Generated